TY - JOUR
T1 - The dopamine D3 receptor (DRD3) gene and risk of schizophrenia
T2 - Case-control studies and an updated meta-analysis
AU - Nunokawa, Ayako
AU - Watanabe, Yuichiro
AU - Kaneko, Naoshi
AU - Sugai, Takuro
AU - Yazaki, Saori
AU - Arinami, Tadao
AU - Ujike, Hiroshi
AU - Inada, Toshiya
AU - Iwata, Nakao
AU - Kunugi, Hiroshi
AU - Sasaki, Tsukasa
AU - Itokawa, Masanari
AU - Ozaki, Norio
AU - Hashimoto, Ryota
AU - Someya, Toshiyuki
N1 - Funding Information:
Funding for this study was provided by a Grant from the Niigata Medical Association (to A.N.), a Grant from the Research Group For Schizophrenia, Japan (to N.K.), a Grant for the Promotion of Niigata University Research Projects (to N.K.), and the Tsukada Memorial Grant for Niigata University Medical Research (to T.S.1). The funding sources had no involvement in the study design; collection, analysis and interpretation of the data; or writing of the report and the decision to submit it for publication.
PY - 2010/1
Y1 - 2010/1
N2 - The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.
AB - The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.
UR - http://www.scopus.com/inward/record.url?scp=71549168918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71549168918&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2009.10.016
DO - 10.1016/j.schres.2009.10.016
M3 - Article
C2 - 19897343
AN - SCOPUS:71549168918
SN - 0920-9964
VL - 116
SP - 61
EP - 67
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1
ER -
